Livoletide

Summary

Livoletide (also known as AZP‑531) is an investigational peptide belonging to the growth‑hormone secretagogue family. It is an acylated analogue of unacylated ghrelin designed for subcutaneous administration. The compound is being explored primarily for the treatment of hyperphagia and associated obesity in individuals with Prader‑Willi syndrome, a rare genetic disorder characterized by an insatiable appetite after early‑life feeding difficulties.

Mechanism of Action

Livoletide is a synthetic analogue of unacylated ghrelin, a hormone that normally circulates without activating the classical growth‑hormone secretagogue receptor (GHSR1a). By mimicking unacylated ghrelin, the peptide is intended to modulate the broader ghrelin signalling network that influences appetite and energy balance. The precise cellular pathways remain under investigation, but the design aims to counteract the excessive ghrelin activity observed in Prader‑Willi syndrome.

What the Research Shows

The only peer‑reviewed source mentioning livoletide is a 2023 narrative review of hyperphagia in Prader‑Willi syndrome. The authors note that livoletide, along with other agents such as topiramate and diazoxide, could potentially alleviate the hormonal abnormalities that drive excessive eating in this condition. No clinical trial data, efficacy outcomes, or safety results are presented in the abstract; the discussion is speculative and based on the drug’s theoretical ability to regulate ghrelin‑related pathways. Consequently, the current evidence base for livoletide consists solely of expert opinion rather than empirical study.

Reported Benefits

According to the review, livoletide may help reduce hyperphagic drive in Prader‑Willi syndrome by targeting the ghrelin system, which is often elevated in affected individuals. If effective, it could lessen caloric intake and mitigate obesity‑related complications. However, these benefits are inferred from the drug’s mechanistic design and have not been demonstrated in human studies, so the potential advantage remains hypothetical pending clinical evaluation.

Limitations of the Evidence

The principal limitation is the absence of published clinical data; the compound is described only in a review that speculates on its utility. No controlled trials, dose‑response information, or comparative efficacy data are available. Moreover, the exact mechanism by which an unacylated ghrelin analogue might counteract hyperphagia is not fully elucidated, and the review does not address long‑term outcomes or patient‑reported effects. Therefore, the current evidence is insufficient to draw conclusions about real‑world effectiveness.

Safety Considerations

Safety information for livoletide is not provided in the available abstract. As an investigational peptide, its adverse‑event profile, tolerability, and contraindications have not been disclosed in peer‑reviewed literature. Until formal clinical trials report safety outcomes, potential risks remain unknown, and use should be confined to controlled research settings under medical supervision.

How It Is Administered

Livoletide is formulated for subcutaneous injection, the route commonly employed for peptide therapeutics. Details regarding dosing frequency, formulation concentration, or device type are not described in the source material and would be defined in future clinical protocols. The subcutaneous route facilitates systemic absorption while avoiding first‑pass metabolism.

Routes of Administration

Goals & Uses

• Body weight / fat mass reductionMetabolicLow
• Reduction of hyperphagia in Prader-Willi syndromeSymptom ManagementModerate
• Behavioral improvement in PWSNeurobehavioralModerate
• Improvement of glycemic parametersMetabolicLow

Contraindications

• Known hypersensitivity to livoletide or excipientsAllergy/HypersensitivityHigh

Adverse Effects

• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• FatigueGeneralUncommonLow energy or tiredness

Drug Interactions

• Growth hormone therapyLow
• Insulin / antidiabetic agentsLow

Population Constraints

• Severe renal or hepatic impairmentOrgan FunctionRelative
• PregnancyReproductive SafetyRelative
• Pediatric patients (under 12 years)AgeRelative

Regulatory Status

• European UnionInvestigationalEMA Orphan Drug Designation granted for Prader-Willi syndrome. No marketing authorization approved.
• United StatesInvestigationalFDA Orphan Drug Designation granted for Prader-Willi syndrome. No approved marketing authorization as of knowledge cutoff.

Livoletide has received Orphan Drug Designation from both the FDA and EMA for Prader-Willi syndrome. It has not received marketing approval in any jurisdiction as of the knowledge cutoff. Phase 2 clinical trials have been conducted.

Evidence & Sources

• Hyperphagia in Prader-Willi syndrome with obesity: From development to pharmacological treatment
  Journal ArticleModerateRahman QFA, Jufri NF, Hamid A2023-01-01T00:00:00.000000Z

Frequently Asked Questions